Plate Nº 81 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Small Post-Infection Costs Can Tip Vaccine Math Toward Elimination, Model Shows
New UBC modeling shows that even small costs from post-infection complications can make aggressive vaccine coverage—and even disease elimination—cost-effective.
By Elena Vasquez5 min read981 words
In brief
- More than 400 million people globally have experienced long COVID symptoms, the study authors note.
- The study, led by UBC's Dr. Chadi Saad-Roy, appears in the Proceedings of the National Academy of Sciences (2026).
- In all three vaccine cost scenarios tested, even small post-infection costs shifted optimal coverage toward elimination.
- Nonpharmaceutical measures like masking and air filtration reduced the share of people vulnerable to post-infection effects.
Even a small price tag attached to post-infection complications can tip the cost-benefit balance in favor of vaccinating enough people to eliminate a disease entirely, according to new mathematical modeling from the University of British Columbia.
The study, published in the Proceedings of the National Academy of Sciences in 2026, suggests that public health officials may be systematically undervaluing vaccines when they plan coverage targets—because standard models rarely count what happens after the acute infection fades.
"Our models indicate even small post-infection costs can tip the scales and make the case for vaccine-driven elimination," said Dr. Chadi Saad-Roy, senior author of the study and an assistant professor in UBC's Department of Mathematics and the Department of Microbiology and Immunology.
Why long-term illness changes the vaccine calculation
The COVID-19 pandemic exposed how the effects of an infection can linger. More than 400 million people worldwide have experienced persistent symptoms known as long COVID. Evidence of post-viral impacts continues to mount across other diseases as well.
Yet the models that guide infectious disease management strategies typically focus only on the acute phase of illness—the days or weeks of active infection. They ignore the downstream consequences that can follow recovery.
To close that gap, the researchers built a system of mathematical equations that captures the interplay between public health interventions and post-infection effects.
"From the perspective of society, there's some cost to producing vaccines, and there's a big benefit to reducing infections and post-infection effects. So, the question is: Where does this optimum happen?" Saad-Roy explained. The answer depends on the disease.
For a benign virus, vaccinating at all may not be worth the expense. For other infections, the ideal strategy may be to vaccinate enough people to wipe the disease out. In many cases, the best target falls somewhere in between. "Our modeling can help answer those questions," he said.
What did the team actually model?
The researchers worked in two stages.
First, they used a classic epidemiological framework—one that divides the population into susceptible, infectious and recovered individuals—to evaluate nonpharmaceutical interventions: measures such as masking, social distancing and air filtration that reduce transmission without drugs or vaccines.
On long timescales, these measures substantially decreased the proportion of people who became infected and then recovered. That matters because recovered individuals are precisely the group vulnerable to lingering post-infection effects. In plain terms, reducing transmission also reduces the pool of people who might later suffer long-term consequences.
Second, the team coupled the epidemiological model with an economic one. Their equations weighed:
- The societal cost of acute infection, such as hospitalization
- The societal cost of long-term infection, including loss of workforce participation
- The cost of vaccination, spanning development, production, distribution and recruitment of recipients
The researchers tested three different scenarios for how vaccination costs change as campaigns scale up:
- Accelerating costs — a first wave of easy-to-reach adopters takes the vaccine, but reaching additional people grows harder due to hesitancy or logistical barriers
- Decelerating costs — initial resistance softens as peer influence makes others more willing to get vaccinated
- Alternating costs — the cost curve accelerates and decelerates in turns
How sensitive is the sweet spot?
The key result was strikingly consistent. In all three cost scenarios, the ideal level of vaccine coverage proved highly sensitive to post-acute effects. Even small post-infection costs pushed the optimal coverage rate higher—and in some cases all the way to elimination.
That finding has a practical implication: health agencies that ignore post-infection burden may be setting vaccination targets too low.
What would it take to apply this in the real world?
The model's usefulness depends on knowing which cost scenario applies in a given setting. That requires socioeconomic studies exploring how people make vaccination decisions in a specific time and place—dynamics that outreach efforts can influence.
First author Prakhar Jaiswal, a graduate student in UBC's Department of Mathematics, pointed to a direct lever: hesitancy itself. "If we can educate people about the benefits of vaccination and reduce hesitancy, that can lower the cost of vaccination and tip the balance in favor of vaccinating to eliminate the disease," he said.
Better data would also sharpen the model. Saad-Roy argued that post-infection symptoms deserve rigorous measurement rather than dismissal. "We need to tackle this rigorously and not dismiss individuals' experiences as anecdotal," he said. Large, long-term cohort studies that survey participants on a broad constellation of symptoms could provide that systematic evidence base.
What are the caveats?
The findings come with clear limits worth keeping in mind.
This is a modeling study, not a clinical trial. Its conclusions describe how an optimal strategy shifts under different assumptions, rather than measuring real-world outcomes in a specific population. The three cost scenarios are stylized simplifications of how vaccination campaigns actually unfold.
The study also does not name particular diseases or attach dollar figures to specific post-infection conditions. Translating its equations into concrete coverage targets for, say, influenza or COVID-19 would require localized data on vaccination costs and post-infection burden that many health systems do not yet collect systematically.
Still, the direction of the result is robust across every scenario the team tested: when post-infection illness carries real cost, the case for vaccinating more people gets stronger—sometimes strong enough to justify elimination.
"These strategies can effectively reduce acute infection, which in turn mitigates post-acute burden and ultimately leads to a healthier world," Saad-Roy said.
The interdisciplinary team includes co-authors Daniel Coombs of UBC Mathematics, Caroline Wagner of McGill Bioengineering, and Troy Day of Queen's Mathematics & Statistics. The paper, "Interventions to mitigate post-infection morbidity: Management insights from simple models," appears in the Proceedings of the National Academy of Sciences (DOI: 10.1073/pnas.2609982123).
via Medical Xpress (Source)
More from Elena Vasquez
Nearby plates
- Nasal Vaccine Additive Kept Mice Alive Against Flu 100 Days Later
- First-in-Human Trial Reports Promising Results for Lassa Fever Vaccine
- Experimental Pill Trial Aims to Slow Congo's Deadliest Ebola Outbreak
- Gut microbes help set the body's inflammatory vaccine response
- NEJM Publishes Trial Results for mRNA Seasonal Flu Vaccine in Adults